Literature DB >> 34021332

Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection - Surveillance for Emerging Threats to Mothers and Babies Network, 22 state, local, and territorial health departments, March 29, 2020 -March 5, 2021.

Romeo R Galang1, Suzanne M Newton1, Kate R Woodworth1, Isabel Griffin1, Titilope Oduyebo1, Christina L Sancken1, Emily O'Malley Olsen1, Kathryn Aveni2, Heather Wingate3, Hanna Shephard4, Chris Fussman5, Zahra S Alaali6, Kristin Silcox7, Samantha Siebman8, Umme-Aiman Halai9, Camille Delgado Lopez10, Mamie Lush11, Ayomide Sokale12, Jerusha Barton13, Ifrah Chaudhary14, Paul H Patrick15, Levi Schlosser16, Bethany Reynolds17, Nicole Gaarenstroom18, Sarah Chicchelly19, Jennifer S Read20,21, Leah de Wilde22, Deborah Mbotha23, Eduardo Azziz-Baumgartner1, Aron J Hall1, Van T Tong1, Sascha Ellington1, Suzanne M Gilboa1.   

Abstract

BACKGROUND: Pregnant women with coronavirus disease 2019 (COVID-19) are at increased risk for severe illness compared with nonpregnant women. Data to assess risk factors for illness severity among pregnant women with COVID-19 are limited. This study aimed to determine risk factors associated with COVID-19 illness severity among pregnant women with SARS-CoV-2 infection.
METHODS: Pregnant women with SARS-CoV-2 infection confirmed by molecular testing were reported during March 29, 2020-March 5, 2021 through the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET). Criteria for illness severity (asymptomatic, mild, moderate-to-severe, or critical) were adapted from National Institutes of Health and World Health Organization criteria. Crude and adjusted risk ratios for moderate-to-severe or critical COVID-19 illness were calculated for selected demographic and clinical characteristics.
RESULTS: Among 7,950 pregnant women with SARS-CoV-2 infection, moderate-to-severe or critical COVID-19 illness was associated with age 25 years and older, healthcare occupation, pre-pregnancy obesity, chronic lung disease, chronic hypertension, and pregestational diabetes mellitus. Risk of moderate-to-severe or critical illness increased with the number of underlying medical or pregnancy-related conditions.
CONCLUSIONS: Older age and having underlying medical conditions were associated with increased risk of moderate-to-severe or critical COVID-19 illness among pregnant women. This information might help pregnant women understand their risk for moderate-to-severe or critical COVID-19 illness and inform targeted public health messaging. Published by Oxford University Press for the Infectious Diseases Society of America 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; illness severity; pregnancy; risk factors

Year:  2021        PMID: 34021332     DOI: 10.1093/cid/ciab432

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.

Authors:  Gonzalo Ferreira; Axel Santander; Florencia Savio; Mariana Guirado; Luis Sobrevia; Garth L Nicolson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-09-03       Impact factor: 5.187

2.  Safety and protective capability of an inactivated SARS-CoV-2 vaccine on pregnancy, lactation and the growth of offspring in hACE2 mice.

Authors:  Kaili Lin; Meixuan Liu; Linlin Bao; Qi Lv; Hua Zhu; Dan Li; Yanfeng Xu; Zhiguang Xiang; Jiangning Liu; Xujian Liang; Yunlin Han; Zhe Cong; Ruixue Liu; Ran Deng; Siyuan Wang; Zhi Guo; Lu Sun; Qiang Wei; Hongwei Qiao; Shunyi Wang; Sidan Pan; Hong Gao; Chuan Qin
Journal:  Vaccine       Date:  2022-06-08       Impact factor: 4.169

Review 3.  COVID-19 disease and vaccination in pregnant and lactating women.

Authors:  Marco A P Safadi; Julia Spinardi; David Swerdlow; Amit Srivastava
Journal:  Am J Reprod Immunol       Date:  2022-05-09       Impact factor: 3.777

Review 4.  COVID-19 in the Critically Ill Pregnant Patient.

Authors:  Matthew Levitus; Scott A Shainker; Mai Colvin
Journal:  Crit Care Clin       Date:  2022-01-10       Impact factor: 3.879

5.  Structural racism and risk of SARS-CoV-2 in pregnancy.

Authors:  Rachel Pope; Prakash Ganesh; Jill Miracle; Romona Brazile; Honor Wolfe; Johnie Rose; Kurt C Stange; Terry Allan; Heidi Gullett
Journal:  EClinicalMedicine       Date:  2021-06-10

6.  Balancing the Risks and Benefits of COVID-19 Vaccination for Pregnant Women and Their Children.

Authors:  Chengliang Yang; Hedi Zhao; Scott J Tebbutt
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

7.  Control and Prevention of SARS-CoV-2 Outbreaks among Healthcare Workers from 129 Healthcare Facilities in Mexico.

Authors:  César Pineda-Santoyo; Abraham Campos-Romero; Marco A Luna-Ruiz Esparza; Liliana E López-Luna; Martha E Sánchez-Zarate; Abraham Zepeda-González; Miguel A Fernández-Rojas; Jonathan Alcántar-Fernández
Journal:  Int J Environ Res Public Health       Date:  2021-11-10       Impact factor: 3.390

Review 8.  An update on COVID-19 and pregnancy.

Authors:  Denise J Jamieson; Sonja A Rasmussen
Journal:  Am J Obstet Gynecol       Date:  2021-09-14       Impact factor: 8.661

9.  Predictors of severe and critical disease in pregnant women with SARS-CoV-2.

Authors:  Meghana A Limaye; Ashley S Roman; Megan E Trostle; Pooja Venkatesh; Meralis Lantigua Martinez; Sara G Brubaker; Judith Chervenak; Lili S Wei; Parita Sahani; Tracy B Grossman; Jessica A Meyer; Christina A Penfield
Journal:  J Matern Fetal Neonatal Med       Date:  2021-09-01

10.  Transmitted Fetal Immune Response in Cases of SARS-CoV-2 Infections during Pregnancy.

Authors:  Ernesto González-Mesa; Eduardo García-Fuentes; Rafael Carvia-Pontiasec; Ana I Lavado-Fernández; Celia Cuenca-Marín; María Suárez-Arana; Marta Blasco-Alonso; Blanca Benítez-Lara; Laura Mozas-Benítez; Ana González-Cazorla; Herink Egeberg-Neverdal; Jesús S Jiménez-López
Journal:  Diagnostics (Basel)       Date:  2022-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.